[{"address1": "3710 \u2013 33rd Street NW", "city": "Calgary", "state": "AB", "zip": "T2L 2M1", "country": "Canada", "phone": "403-455-7727", "website": "https://www.xortx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease. Its drug development programs include XRx-026, which is in the third phase for the treatment of gout; XRx-008, which is in the second phase to treat autosomal dominant polycystic kidney disease; XRx-101, which is in the second phase to treat acute kidney injury associated with respiratory virus infection; and XRX-225, which is in the preclinical stage for the treatment of type 2 diabetic nephropathy. It has a license agreement with the University of Florida Research Foundation, Inc. for the use of uric acid lowering agent to treat insulin resistance. The company is based in Calgary, Canada.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Allen Warren Davidoff Ph.D.", "age": 64, "title": "Founder, CEO, President & Director", "yearBorn": 1960, "fiscalYear": 2024, "totalPay": 391655, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Nick  Rigopoulos", "title": "Director of Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David  Sans M.B.A., Ph.D.", "age": 54, "title": "Director of Corporate Development", "yearBorn": 1970, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David  MacDonald Ph.D.", "age": 60, "title": "Consultant of Clinical Operations", "yearBorn": 1964, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Charlotte  May", "title": "Corporate Secretary", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.94, "open": 0.984, "dayLow": 0.9676, "dayHigh": 1.09, "regularMarketPreviousClose": 0.94, "regularMarketOpen": 0.984, "regularMarketDayLow": 0.9676, "regularMarketDayHigh": 1.09, "payoutRatio": 0.0, "beta": 0.027, "forwardPE": -0.64071864, "volume": 180698, "regularMarketVolume": 180698, "averageVolume": 50414, "averageVolume10days": 19800, "averageDailyVolume10Day": 19800, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "marketCap": 4053427, "fiftyTwoWeekLow": 0.802, "fiftyTwoWeekHigh": 2.98, "fiftyDayAverage": 0.97154, "twoHundredDayAverage": 1.263355, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1618559, "profitMargins": 0.0, "floatShares": 3305586, "sharesOutstanding": 3788250, "sharesShort": 23311, "sharesShortPriorMonth": 34099, "sharesShortPreviousMonthDate": 1743379200, "dateShortInterest": 1745971200, "sharesPercentSharesOut": 0.0062, "heldPercentInsiders": 0.03507, "heldPercentInstitutions": 0.000120000004, "shortRatio": 0.4, "shortPercentOfFloat": 0.0063, "impliedSharesOutstanding": 3901400, "bookValue": 0.958, "priceToBook": 1.1169103, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "earningsQuarterlyGrowth": -0.955, "netIncomeToCommon": -3313346, "trailingEps": -1.15, "forwardEps": -1.67, "lastSplitFactor": "1:9", "lastSplitDate": 1699920000, "enterpriseToEbitda": -0.628, "52WeekChange": -0.61841035, "SandP52WeekChange": 0.11469197, "quoteType": "EQUITY", "currentPrice": 1.07, "targetHighPrice": 14.341568, "targetLowPrice": 14.341568, "targetMeanPrice": 14.341568, "targetMedianPrice": 14.341568, "recommendationKey": "none", "numberOfAnalystOpinions": 1, "totalCash": 2473649, "totalCashPerShare": 0.653, "ebitda": -2577996, "totalDebt": 38785, "quickRatio": 3.287, "currentRatio": 3.531, "debtToEquity": 1.162, "returnOnAssets": -0.34206, "returnOnEquity": -0.83055997, "freeCashflow": -1111743, "operatingCashflow": -3678648, "earningsGrowth": -0.972, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "XRTX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": 13.829793, "regularMarketPrice": 1.07, "exchange": "NCM", "messageBoardId": "finmb_259860883", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "corporateActions": [], "postMarketTime": 1747439540, "regularMarketTime": 1747425600, "marketState": "CLOSED", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1632403800000, "postMarketChangePercent": 3.73831, "postMarketPrice": 1.11, "postMarketChange": 0.04, "regularMarketChange": 0.13000005, "regularMarketDayRange": "0.9676 - 1.09", "shortName": "XORTX Therapeutics Inc.", "longName": "XORTX Therapeutics Inc.", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 50414, "fiftyTwoWeekLowChange": 0.26800007, "fiftyTwoWeekLowChangePercent": 0.33416468, "fiftyTwoWeekRange": "0.802 - 2.98", "fiftyTwoWeekHighChange": -1.91, "fiftyTwoWeekHighChangePercent": -0.6409396, "fiftyTwoWeekChangePercent": -61.841034, "earningsTimestamp": 1743451200, "earningsTimestampStart": 1747684800, "earningsTimestampEnd": 1748116800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.15, "epsForward": -1.67, "epsCurrentYear": -1.574, "priceEpsCurrentYear": -0.67979676, "fiftyDayAverageChange": 0.09846008, "fiftyDayAverageChangePercent": 0.10134434, "twoHundredDayAverageChange": -0.19335496, "twoHundredDayAverageChangePercent": -0.1530488, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-10-13", "cryptoTradeable": false, "displayName": "XORTX Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-05-17"}]